Intravenous Immunoglobulin in the Treatment of Primary Immunodeficiency Diseases

被引：19

作者：

De Ranieri, Deirdre ^{[1
,2
]}

Fenny, Nana Sarkoah ^{[2
,3
,4
,5
]}

机构：

[1] Comer Childrens Hosp, Sect Pediat Rheumatol, Chicago, IL USA

[2] Univ Chicago, Pediat, Chicago, IL 60637 USA

[3] Comer Childrens Hosp, Sect Allergy & Immunol, Chicago, IL USA

[4] Univ Chicago, Med, Chicago, IL 60637 USA

[5] Univ Chicago Med, Sect Pulm Crit Care, Chicago, IL USA

来源：

PEDIATRIC ANNALS | 2017年 / 46卷 / 01期

关键词：

SUBCUTANEOUS IGG; DIAGNOSIS; THERAPY; IVIG;

D O I：

10.3928/19382359-20161213-03

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Intravenous immunoglobulin (IVIG) has been used as antibody replacement therapy in primary immunodeficiency diseases (PIDDs) for more than 50 years. Its role as a therapeutic agent has expanded over the past couple of decades as its anti-inflammatory and immune-modulatory mechanisms of action have been elucidated. It is now used "off-label" to treat other autoimmune diseases. This article focuses on the role of IVIG in the treatment of PIDDs characterized by absent or deficient antibody production. Replacement doses are given on a monthly basis in these conditions as a prophylactic measure to prevent acute and serious bacterial infections.

引用

页码：E8 / E12

页数：5

共 22 条

[1] Common Variable Immunodeficiency Diagnosis, Management, and Treatment [J].

Abbott, Jordan K. ;

Gelfand, Erwin W. .

IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2015, 35 (04) :637-+

[2] Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency [J].

Al-Herz, Waleed ;

Bousfiha, Aziz ;

Casanova, Jean-Laurent ;

Chatila, Talal ;

Conley, Mary Ellen ;

Cunningham-Rundles, Charlotte ;

Etzioni, Amos ;

Franco, Jose Luis ;

Gaspar, H. Bobby ;

Holland, Steven M. ;

Klein, Christoph ;

Nonoyama, Shigeaki ;

Ochs, Hans D. ;

Oksenhendler, Erik ;

Picard, Capucine ;

Puck, Jennifer M. ;

Sullivan, Kate ;

Tang, Mimi L. K. .

FRONTIERS IN IMMUNOLOGY, 2014, 5

[3] Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose [J].

Berger, Melvin .

CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 11 (06) :532-538

[4] New frontiers in immunology - Workshop on the Road Ahead: Future Directions in Fundamental and Clinical Immunology [J].

Beutler, B ;

Casanova, JL .

EMBO REPORTS, 2005, 6 (07) :620-623

[5] Illustrative cases on individualizing immunoglobulin therapy in primary immunodeficiency disease [J].

Bonagura, Vincent R. .

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2013, 111 (06) :S10-S13

[6] Using Intravenous Immunoglobulin (IVIG) to Treat Patients with Primary Immune Deficiency Disease [J].

Bonagura, Vincent R. .

JOURNAL OF CLINICAL IMMUNOLOGY, 2013, 33 :S90-S94

[7]

BRUTON OC, 1952, PEDIATRICS, V9, P722

[8] Subcutaneous IgG in immune-mediate diseases: proposed mechanisms of action and literature review [J].

Danieli, Maria Giovanna ;

Gelardi, Chiara ;

Pedini, Veronica ;

Moretti, Romina ;

Gabrielli, Armando ;

Logullo, Francesco .

AUTOIMMUNITY REVIEWS, 2014, 13 (12) :1182-1188

[9]

European Society for Immunodeficiencies, NEW CLIN DIAGN CRIT

[10]

Gatti R., 1993, GeneReviews()

← 1 2 3 →